Literature DB >> 23708197

Radiolabeled amino acids for oncologic imaging.

Chaofeng Huang1, Jonathan McConathy.   

Abstract

Radiolabeled amino acids (AAs) are an important class of imaging agents for PET and SPECT that target the increased levels of AA transport by many tumor cells. System L AA transport has been a major focus of tracer development, and work in this field has led to several tracers that are effective for imaging brain tumors. Emerging data also support the use of certain radiolabeled AAs for neuroendocrine tumors and prostate cancer. Recently, new (18)F-labeled AAs have been developed that target transporters other than system L, including system A, glutamine, xCT, and cationic AA transporters. This review provides an overview of this class of molecular imaging agents and highlights the current status of oncologic imaging with radiolabeled AAs in terms of tracer considerations and key clinical applications.

Entities:  

Keywords:  PET; SPECT; amino acids; tumor imaging

Mesh:

Substances:

Year:  2013        PMID: 23708197     DOI: 10.2967/jnumed.112.113100

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  39 in total

1.  System a amino acid transport-targeted brain and systemic tumor PET imaging agents 2-amino-3-[(18)F]fluoro-2-methylpropanoic acid and 3-[(18)F]fluoro-2-methyl-2-(methylamino)propanoic acid.

Authors:  Weiping Yu; Jonathan McConathy; Jeffrey J Olson; Mark M Goodman
Journal:  Nucl Med Biol       Date:  2014-08-01       Impact factor: 2.408

Review 2.  Molecular Imaging of Membrane Transporters' Activity in Cancer: a Picture is Worth a Thousand Tubes.

Authors:  Aniv Mann; Inessa Semenenko; Michal Meir; Sara Eyal
Journal:  AAPS J       Date:  2015-03-31       Impact factor: 4.009

Review 3.  PET Tracers Beyond FDG in Prostate Cancer.

Authors:  David M Schuster; Cristina Nanni; Stefano Fanti
Journal:  Semin Nucl Med       Date:  2016-09-07       Impact factor: 4.446

4.  Prospective evaluation of 18F-FACBC PET/CT and PET/MRI versus multiparametric MRI in intermediate- to high-risk prostate cancer patients (FLUCIPRO trial).

Authors:  Ivan Jambor; Anna Kuisma; Esa Kähkönen; Jukka Kemppainen; Harri Merisaari; Olli Eskola; Jarmo Teuho; Ileana Montoya Perez; Marko Pesola; Hannu J Aronen; Peter J Boström; Pekka Taimen; Heikki Minn
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-11-16       Impact factor: 9.236

Review 5.  From Carbon-11-Labeled Amino Acids to Peptides in Positron Emission Tomography: the Synthesis and Clinical Application.

Authors:  Aleksandra Pekošak; Ulrike Filp; Alex J Poot; Albert D Windhorst
Journal:  Mol Imaging Biol       Date:  2018-08       Impact factor: 3.488

6.  High-Yielding Automated Convergent Synthesis of No-Carrier-Added [11C-Carbonyl]-Labeled Amino Acids Using the Strecker Reaction.

Authors:  Junhao Xing; Allen F Brooks; Dylan Fink; Huibin Zhang; Morand R Piert; Peter J H Scott; Xia Shao
Journal:  Synlett       Date:  2016-11-07       Impact factor: 2.454

7.  Anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid: physiologic uptake patterns, incidental findings, and variants that may simulate disease.

Authors:  David M Schuster; Cristina Nanni; Stefano Fanti; Shuntaro Oka; Hiroyuki Okudaira; Yusuke Inoue; Jens Sörensen; Rikard Owenius; Peter Choyke; Baris Turkbey; Trond V Bogsrud; Tore Bach-Gansmo; Raghuveer K Halkar; Jonathon A Nye; Oluwaseun A Odewole; Bital Savir-Baruch; Mark M Goodman
Journal:  J Nucl Med       Date:  2014-11-13       Impact factor: 10.057

Review 8.  From the clinician's point of view - What is the status quo of positron emission tomography in patients with brain tumors?

Authors:  Norbert Galldiks; Karl-Josef Langen; Whitney B Pope
Journal:  Neuro Oncol       Date:  2015-06-30       Impact factor: 12.300

9.  PET imaging in patients with brain metastasis-report of the RANO/PET group.

Authors:  Norbert Galldiks; Karl-Josef Langen; Nathalie L Albert; Marc Chamberlain; Riccardo Soffietti; Michelle M Kim; Ian Law; Emilie Le Rhun; Susan Chang; Julian Schwarting; Stephanie E Combs; Matthias Preusser; Peter Forsyth; Whitney Pope; Michael Weller; Jörg C Tonn
Journal:  Neuro Oncol       Date:  2019-05-06       Impact factor: 12.300

Review 10.  PET in the management of locally advanced and metastatic NSCLC.

Authors:  Willem Grootjans; Lioe-Fee de Geus-Oei; Esther G C Troost; Eric P Visser; Wim J G Oyen; Johan Bussink
Journal:  Nat Rev Clin Oncol       Date:  2015-04-28       Impact factor: 66.675

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.